California-based Caribou Biosciences, one of the upstart leaders in developing CRISPR-Cas9 technologies for precision cell engineering, has closed an $11 million Series A financing round. The group of investors include pharma giant Novartis, Fidelity Biosciences, Mission Bay Capital, 5 Prime Ventures and an undisclosed strategic partner. Additionally, Dr. Jennifer Doudna, …